In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...